References
- Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020a Mar 18:1–7. doi:https://doi.org/10.1080/21645515.2020.1735227.
- Yatoo MI, Hamid Z, Parray OR, Wani AH, Wani A, Saxena A, Patel SK, Pathak M, Tiwari R, Malik YS, et al..COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines. Human Vaccin Immunother. 2020. doi:https://doi.org/10.1080/21645515.2020.1788310.
- Cox JC, Coulter AR. Adjuvants - a classification and review of their modes of action. Vaccin. 1997;15:248–56. doi:https://doi.org/10.1016/S0264-410X(96)00183-1.
- Singh M, O’Hagan D T. Recent advances in veterinary vaccine adjuvants. Internat J Parasitol. 2003;33:469–78.
- Van Dyck S, Flammang P, Meriaux C, Bonnel D, Salzet M, Fournier I, Wisztorski M. Localization of secondary metabolites in marine invertebrates: contribution of MALDI MSI for tH. Study of saponins in cuvierian tubules of H. forskali. PLoS One. 2010;5:e13923. doi:https://doi.org/10.1371/journal.pone.0013923.
- Hostettmann KA, Marston A. Chemistry and Pharmacology of Natural Products: Saponins. Cambridge, New York: Cambridge Univ. Press;1995.
- Kregiel D, Berlowska J, Witonska I, Antolak H, Proestos C, Babic M, Babic L, Zhang B. Saponin-based, biological-active surfactants from plants. Applicn Charactn Surfact. 2017;183–205. http://dx.doi.org/10.5772/68062
- Didierlaurent AM, Laupèze B, Pasquale AD, Hergli N, Collignon C, Garçon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16(1):55–63. doi:https://doi.org/10.1080/14760584.2016.1213632.
- van Braeckel E, Buorgognon P, Koutsokos M, Clement F, Jensens M, Carletti I, Collard A, Demoitie MA, Voss G, Leroux-Roels G, McNally L. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Inf Dis. 2011;54:522–31. doi:https://doi.org/10.1093/cid/ciq160.
- Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitié MA, Mettens P, Moris P, Ledent E, Leroux-Roels G, Ofori-Anyinam O, M72 Study Group. Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine. 2013;31(17):2196–206. doi:https://doi.org/10.1016/j.vaccine.2012.05.035.
- Ren W, Sun H, Gao GF, Chen J, Sun S, Zhao R, Gao G, Hu Y, Zhao G, Chen Y, et al.. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates. Vaccine. 2020;38(35):5653–58. doi:https://doi.org/10.1016/j.vaccine.2020.06.066.
- Bisht H, Roberts A, Vogel L, Subbarao K, Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology. 2005;334:160–65. doi:https://doi.org/10.1016/j.virol.2005.01.042.
- El Aziz MMA, Ashour AS, Melad ASG. A review on saponins from medicinal plants: chemistry, isolation, and determination. J Nanomed Res. 2019;7(4):282 ‒288. doi:https://doi.org/10.15406/jnmr.2019.07.00199.
- Saxena M, Saxena J, Nema R, Singh D, Gupta A. Phytochemistry of medicinal plants. J Pharmacog Phytochem. 2013;1:168–82.
- Springob K, Kutchan TM. Introduction to the different classes of natural products. In: Plant-derived natural products. Editor(s): Osbourn AE, Lanzotti V. New York (NY): Springer; 2009. p. 3–50.
- Szakiel A, Ruszkowski D, Janiszowska W. Saponins in Calendula officinalis L. -structure, biosynthesis, transport and biological activity. Phytochem Rev. 2005;4:151–58. doi:https://doi.org/10.1007/s11101‐005‐4053‐9.
- Vincken JP, Heng L, de Groot A, Gruppen H. Saponins, classification and occurrence in the plant kingdom.. Phytochem. 2007;68(3):275–97. doi:https://doi.org/10.1016/j.phytochem.2006.10.008.
- Oleszek W, Hamed A. Saponin‐based surfactants. In: Kjellin M, Johansson I, editors. Surfactants from renewable sources resources. Chichester (UK): John Wiley & Sons Ltd; 2010. p. 239–49. doi:https://doi.org/10.1002/9780470686607.ch12.
- Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol. 2007;5(7):396–97. doi:https://doi.org/10.1038/nrmicro1681.
- Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114. doi:https://doi.org/10.3389/fimmu.2013.00114.
- Siskind GW, Benacerraf B. Cell selection by antigen in the immune response. Adv Immunol. 1969;10:1–50.
- Glenny AT, Pope CG, Waddington H, Wallace V. The antigenic value of toxoid precipitated by potassium-alum. J Pathol Bacteriol. 1926;29:38–45.
- Osebold JW. Mechanisms of action by immunologic adjuvants. J Am Vet Med Assoc. 1982;181:983–87.
- Herbert WJ. The mode of action of mineral-oil emulsion adjuvants on antibody production in mice. Immunol. 1968;14:301–18.
- Kreuter J. Possibilities of using nanoparticles as carriers for drugs and vaccines. J Microencapn. 1988;5(2):115–27. doi:https://doi.org/10.3109/02652048809056475.
- Goto N, Akama K. Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid. Microbiol Immunol. 1982;26:1121–32. doi:https://doi.org/10.1111/j.1348-0421.1982.tb00261.x.
- Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O’Hagan D, Rappuoli R, De Gregorio E. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci. U.S.A. 2008;105:10501–06. doi:https://doi.org/10.1073/pnas.0804699105.
- He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother. 2015;11(2):477–88. doi:https://doi.org/10.1080/21645515.2014.1004026.
- Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O’Hagan DT, De Gregorio E, Seubert A, Wack A. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccin. 2011;29:1812–23. doi:https://doi.org/10.1016/j.vaccine.2010.12.090.
- Seubert A, Monaci E, Pizza M, O’Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol. 2008;180:5402–12. doi:https://doi.org/10.4049/jimmunol.180.8.5402.
- Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H. Adjuvant system AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccin. 2011;29:2461–73. doi:https://doi.org/10.1016/j.vaccine.2011.01.011.
- Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, et al.. AS04, an aluminum salt- and TLR4 agonist based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009;183:6186–97. doi:https://doi.org/10.4049/jimmunol.0901474.
- Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci. U.S.A. 1996;93:2879–83.
- Klaschik S, Tross D, Klinman DM. Inductive and suppressive networks regulate TLR9- dependent gene expression in vivo. J Leukoc Biol. 2009;85:788–95. doi:https://doi.org/10.1189/jlb.1008671.
- Nanishi E, Dowling DJ, levy O. Towards precision adjuvants: optimizing science and safety. Curr Opin Pediatr. 2020;32(1):125–38. doi:https://doi.org/10.1097/MOP.0000000000000868.
- Guery JC, Ria F, Adorini L. Dendritic cells but not B cells present antigenic complexes to class II-restricted T cells after administration of protein in adjuvant. J Exp Med. 1996;183:751–57.
- Schijns VEJC, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccin. 2011;10:539–50. doi:https://doi.org/10.1586/erv.11.21.
- Ghimire TR, Benson RA, Garside P, Brewer JM. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol Lett. 2012;147:55–62. doi:https://doi.org/10.1016/j.imlet.2012.06.002.
- Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine. 2009;27(12):1787–96. doi:https://doi.org/10.1016/j.vaccine.2009.01.091.
- Marty-Roix R, Vladimer GI, Pouliot K, Weng D, Buglione-Corbett R, West K, MacMicking JD, Chee JD, Wang S, Lu S, et al.. Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants. J Biol Chem. 2016;291(3):1123–36. doi:https://doi.org/10.1074/jbc.M115.683011.
- Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, et al.. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol. 2011;187(1):55–63. doi:https://doi.org/10.4049/jimmunol.1004114.
- Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677. doi:https://doi.org/10.1038/nm.3893.
- Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–65. doi:https://doi.org/10.1146/annurev.immunol.021908.132715.
- Oleszycka E, Lavelle EC. Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol. 2014;28C:1–5. doi:https://doi.org/10.1016/j.coi.2013.12.007.
- Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, et al.. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009;183:6186–97. doi:https://doi.org/10.4049/jimmunol.0901474.
- Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9:847–56. doi:https://doi.org/10.1038/ni.1631.
- Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3. J Immunol. 2008;181:17–21. doi:https://doi.org/10.4049/jimmunol.181.1.17.
- Marty-Roix R, Vladimer GI, Pouliot K, Weng D, Buglione-Corbett R, West K, MacMicking JD, Chee JD, Wang S, Lu S, et al.. Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants. J Biol Chem. 2015;291:1123-1136.
- Kashala O, Amador R, Valero MV, Moreno A, Barbosa A, Nickel B, Daubenberger CA, Guzman F, Pluschke G, Patarroyo ME. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccin. 2002;20:2263–77. doi:https://doi.org/10.1016/S0264-410X(02)00115-9.
- Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS, Livingston PO. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccin. 1999;18:597–603. doi:https://doi.org/10.1016/S0264-410X(99)00316-3.
- Kennedy JS, Co M, Green S, Longtine K, Longtine J, O’Neill MA, Adams JP, Rothman AL, Yu Q, Johnson-Leva R, et al.. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccin. 2008;26:4420–24. doi:https://doi.org/10.1016/j.vaccine.2008.05.090.
- Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, et al.. QS-21 adjuvant activates NLRP3 inflammasome promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccin. 2001;19:2080–91. doi:https://doi.org/10.1016/S0264-410X(00)00415-1.
- Gin DY, Slovin SF. Enhancing immunogenicity of cancer vaccines: QS-21 as an immune adjuvant. Curr Drug Ther. 2011;6:207–12. doi:https://doi.org/10.2174/157488511796391988.
- Krug LM, Ragupathi G, Hood C, George C, Hong F, Shen R, Abrey L, Jennings HJ, Kris MG, Livingston PO. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer Immunol Immunother. 2011;61:9–18. doi:https://doi.org/10.1007/s00262-011-1083-6.
- Vandepapeliere P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, et al.. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccin. 2008;26:1375–86. doi:https://doi.org/10.1016/j.vaccine.2007.12.038.
- Partnership RCT. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45.
- Tin MM, Cho CH, Chan K, James AE, Ko JK. Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft. Carcinogenesis. 2007;28(6):1347–55. doi:https://doi.org/10.1093/carcin/bgl238.
- Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De Kock E, Pavithran P, Koutsoukos M, Moris P, Cain D, Dubois M-C, et al.. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum Vaccin. 2009;5(7):475–82. doi:https://doi.org/10.4161/hv.8570.
- Vellas B, Black R, Thal L, Fox N, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M, et al.. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res. 2009;6(2):144–51. doi:https://doi.org/10.2174/156720509787602852.
- Jie YH, Cammisuli S, Baggiolini M. Immunomodulatory effects of Panax ginseng C. A. Meyer in the mouse. Agents Actions. 1984;15:386–91. doi:https://doi.org/10.1007/BF01972376.
- Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst. 1996;13:1–55.
- Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8:934–43. doi:https://doi.org/10.1016/S1359-6446(03)02864-2.
- Sjolander A, Drane D, Maraskovsky E, Scheerlinck JP, Suhrbier A, Tennent J, Pearse M. Immune responses to ISCOM® formulations in animal and primate models. Vaccin. 2001;19(17–19):2661–65. doi:https://doi.org/10.1016/S0264-410X(00)00497-7.
- Bomford R, Stapleton M, Winsor S, Beesley JE, Jessup EA, Price KR, Fenwick GR. Adjuvanticity and ISCOM formation by structurally diverse saponins. Vaccin. 1992;10(9):572–77. doi:https://doi.org/10.1016/0264-410X(92)90435-M.
- Oda K, Matsuda H, Murakami T, Katayama S, Ohgitani T, Yoshikawa M. Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants. Biolog Chem. 2000;381:67–74.
- Soltysik S, Wu JY, Recchia J, Wheeler DA, Newma MJ, Coughlin RT, Kensil CR. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccin. 1995;13(15):1403–10. doi:https://doi.org/10.1016/0264-410X(95)00077-E.
- Press JB, Reynolds RC, May RD, Marciani DJ. Structure/function relationships of immunostimulating saponins. Studies in Nat Prod Chem. 2000;24:131–74.
- Marciani DJ. New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies. Drug Discov Today. 2014;19:912–20. doi:https://doi.org/10.1016/j.drudis.2014.02.015.
- Marciani DJ, Reynolds RC, Pathak AK, Finley-Woodman K, May RD. Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccin. 2003;21:3961–71. doi:https://doi.org/10.1016/S0264-410X(03)00298-6.
- Nico D, Santos FN, Borja-Cabrera GP, Palatnik M, de Sousa CP. Assessment of the monoterpene, glycidic and triterpene-moieties’ contributions to the adjuvant function of the CP05 saponin of Calliandra pulcherrima Benth during vaccination against experimental visceral leishmaniasis. Vaccin. 2007;25(4):649–58. doi:https://doi.org/10.1016/j.vaccine.2006.08.035.
- Oda K, Matsuda H, Murakami T, Katayama S, Ohgitani T, Yoshikawa M. Relationship between adjuvant activity and amphipathic structure of soyasaponins. Vaccin. 2003;21(17–18):2145–51. doi:https://doi.org/10.1016/S0264-410X(02)00739-9.
- Estrada A, Katselis GS, Laarveld B, Barl B. Isolation and evaluation of immunological adjuvant activities of saponins from Polygala senega L. Comp Immunol Microbiol Infect Dis. 2000;23(1):27–43. doi:https://doi.org/10.1016/S0147-9571(99)00020-X.
- Baumann E, Stoya G, Volkner A, Richter W, Lemke C, Linss W. Hemolysis of human erythrocytes with saponin affects the membrane structure. Acta Histochem. 2000;102(1):21–35. doi:https://doi.org/10.1078/0065-1281-00534.
- Armah CN, Mackie AR, Roy C, Price K, Osbourn AE, Bowyer P, Ladha S. The membrane-permeabilizing effect of avenacin A-1 involves the reorganization of bilayer cholesterol. Biophys J. 1999;76(1):281–90. doi:https://doi.org/10.1016/S0006-3495(99)77196-1.
- Gogelein H, Huby A. Interaction of saponin and digitonin with black lipid membranes and lipid monolayers. BBA-Biomembranes. 1984;773(1):32–38. doi:https://doi.org/10.1016/0005-2736(84)90547-9.
- Keukens EA, de Vrije T, van den Boom C, de Waard P, Plasman HH, Thiel F, Chupin V, Jongen WM, de Kruijff B. Molecular basis of glycoalkaloid induced membrane disruption. BBA-Biomembranes. 1995;1240(2):216–28. doi:https://doi.org/10.1016/0005-2736(95)00186-7.
- Nishikawa M, Nojima S, Akiyama T, Sankawa U, Inoue K. Interaction of digitonin and its analogs with membrane cholesterol. J Biochem. 1984;96(4):1231–39. doi:https://doi.org/10.1093/oxfordjournals.jbchem.a134941.
- Mazzucchelli GD, Cellier NA, Mshviladzade V, Elias R, Shim YH, Touboul D, Quinton L, Brunelle A, Laprevote O, De Pauw EA, et al.. Pores formation on cell membranes by hederacolchiside A1 leads to a rapid release of proteins for cytosolic subproteome analysis. J Proteom Res. 2008;7(4):1683–92. doi:https://doi.org/10.1021/pr7006973.
- Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44:183–93. doi:https://doi.org/10.1006/phrs.2001.0847.
- Kwak WJ, Han CK, Chang HW, Kim HP, Kang SS, Son KH, Loniceroside C. An anti-inflammatory saponin from Lonicera japonica. Chem Pharmaceut Bull. 2003;51:333–35. doi:https://doi.org/10.1248/cpb.51.333.
- da Silva BP, De Sousa AC, Silva GM, Mendes TP, Parente JP. A new bioactive steroidal saponin from Agave attenuata. J Biosci Sec C. 2002;57:423–28.
- Kim DS, Oh SR, Lee IS, Jung KY, Park JD, Kim SI, Lee HK. Anti-complementary activity of Ginseng saponins and their degradation products. Phytochem. 1998;47:397–99. doi:https://doi.org/10.1016/S0031-9422(97)00580-3.
- Conforti F, Marrelli M, Carmela C, Menichini F, Valentina P, Uzunov D, Statti GA, Duez P, Menichini F. Bioactive phytonutrients (omega fatty acids, tocopherols, polyphenols), in vitro inhibition of nitric oxide production and free radical scavenging activity of non-cultivated Mediterranean vegetables. Food Chemi. 2011;129(4):1413–19. doi:https://doi.org/10.1016/j.foodchem.2011.05.085.
- Singh R, Sharma R, Mal G, Varshney R. A comparative analysis of saponin-enriched fraction from Silene vulgaris (Moench) Garcke, Sapindus mukorossi (Gaertn) and Chlorophytum borivilianum (Santapau and Fernandes): an in vitro hemolytic and cytotoxicity evaluation. Ani Biotech. 2020. doi:https://doi.org/10.1080/10495398.2020.1775627.
- Killeen GF, Madigan CA, Connolly CR, Walsh GA, Clark C, Hynes MJ, Timmins BF, James P, Headon DR, Power RF. Antimicrobial saponins of Yucca schidigera and the implications of their in vitro properties for their in vivo impact. J Agricul Food Chem. 1998;46:3178–86. doi:https://doi.org/10.1021/jf970928j.
- ElSohly HN, Danner S, Li XC, Nimrod AC, Clark AM. New anti-mycobacterial saponin from Colubrina retusa. J Nat Prod. 1999;62:1341–42. doi:https://doi.org/10.1021/np9901940.
- Jassim SA, Naji MA. Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol. 2003;95:412–27. doi:https://doi.org/10.1046/j.1365-2672.2003.02026.x.
- Subba Rao G, Sinsheimer JE, Cochran KW. Antiviral activity of triterpenoid saponins containing acylated-amyrin aglycones. J Pharm Sci. 1974;63:471–73. doi:https://doi.org/10.1002/jps.2600630341.
- Sinsheimer JE, Rao GS, Mc Ilhenny HM, Smith RV, Maassab HF, Cochran KW. Isolation and antiviral activity of the gymnemic acids. Experientia. 1968;24(302–303):89. doi:https://doi.org/10.1007/BF02152834.
- Gosse B, Gnabre J, Bates RB, Dicus CW, Nakkiew P, Huang RCC. Antiviral saponins from Tieghemella heckelii. J Nat Prod. 2002;65:1942–44. doi:https://doi.org/10.1021/np020165g.
- Sindambiwe JB, Calomme M, Geerts S, Pieters L, Vlietinck AJ, VandenBerghe DA. Evaluation of biological activities of triterpenoid saponins from Maesa lanceolata. J Nat Prod. 1998;61:585–90. doi:https://doi.org/10.1021/np9705165.
- Kinjo J, Yokomizo K, Hirakawa T, Shii Y, Nohara T, Uyeda M. Anti-herpes virus activity of fabaceous triterpenoidal saponins. Biolog Pharmaceut Bull. 2000;23:887–89. doi:https://doi.org/10.1248/bpb.23.887.
- Simoes CMO, Amoros M, Girre L. Mechanism of antiviral activity of triterpenoid saponins. Phytother Res. 1999;13:323–28. doi:https://doi.org/10.1002/(SICI)1099-1573(199906)13:4<323::AID-PTR448>3.0.CO;2-C.
- Bushneva OA, Ovodova RG, Shashkov AS, Chizhov AO, Ovodov YS. Structure of silenan, a pectic polysaccharide from campion Silene vulgaris (Moench) Garcke. Biochem. (Moscow). 2003;68:1360–68.
- Ghonime M, Eldomany R, Abdelaziz A, Soliman H. Evaluation of immunomodulatory effect of three herbal plants growing in Egypt. Immunopharmacol Immunotoxicol. 2011;33(1):141–45. doi:https://doi.org/10.3109/08923973.2010.487490.
- Rivera E, Ekholm Pettersson F, Inganas M, Paulie S, Gronvik KO. The Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response. Vaccin. 2005;23(46–47):5411–19. doi:https://doi.org/10.1016/j.vaccine.2005.04.007.
- Bachran C, Bachran S, Sutherland M, Bachran D, Fuchs H. Saponins in tumor therapy. Mini Rev Med Chem. 2008;8(6):575–84. doi:https://doi.org/10.2174/138955708784534445.
- Sung MK, Kendall CWC, Rao AV. Effect of soybean saponins and gypsophila saponin on morphology of colon carcinoma cells in culture. Food Chem Toxicol. 1995;33(5):357–66. doi:https://doi.org/10.1016/0278-6915(95)00007-O.
- Ragupathi G, Gardner JR, Livingston PO, Gin DY. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccin. 2011;10(4):463–70. doi:https://doi.org/10.1586/erv.11.18.
- Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana DK, Rodriguez-Morales AJ. Coronavirus disease 2019–COVID-19. Clin Microbiol Rev. 2020b;33:e00028–20. doi:https://doi.org/10.1128/CMR.00028-20.
- Gorbalenya AE, Baker SC, Baric RS, deGroot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D, Perlman S, Poon LLM, Samborskiy DV, Sidorov IA, Sola I, Ziebuhr J. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020. doi:https://doi.org/10.1038/s41564-020-0695-z.
- Kupferschmidt K, Cohen J. Will novel virus go pandemic or be contained? Sci. 2020;367:610–11.
- Malik YS, Kumar N, Sircar S, Kaushik R, Bhat S, Dhama K, Gupta P, Goyal K, Singh MP, Ghoshal U, et al.. Coronavirus disease pandemic (COVID-19): challenges and a global perspective. Pathog. 2020 Jun 28;9(7):E519. doi:https://doi.org/10.3390/pathogens9070519.
- Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trend Microbiol. 2016;24(6):490–502. doi:https://doi.org/10.1016/j.tim.2016.03.003.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al.. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020;382(8):727–33. doi:https://doi.org/10.1056/NEJMoa2001017.
- Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;11:298.
- Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 2020;9:275–77. doi:https://doi.org/10.1080/22221751.2020.1723441.
- Guo S, Kenne L. Structural studies of triterpenoid saponins with new acyl components from Quillaja saponaria Molina. Phytochem. 2000;55(5):419–28. doi:https://doi.org/10.1016/S0031-9422(00)00340-X.
- Dalsgaard K. Saponin adjuvants. Archiv Virol. 1974;44:243–54.
- Didierlaurent AM, Berger A, Heineman TC, Henderickx V, Da Silva FT, Vekemans J, Voss G, Garçon N. The development of the adjuvant system AS01: a combination of two immunostimulants MPL and QS-21 in liposomes. In Immunopotentiators Mod Vaccin. (Second Edition) 2017; 265–85. Academic Press, Elsevier.
- Britt W, Fay J, Seals J, Kensil C. Formulation of immunogenic human cytomegalovirus vaccine: responses in mice. J Infect Dis. 1995;171:18–25. doi:https://doi.org/10.1093/infdis/171.1.18.
- Lovgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complex. Stand J Lmmunol. 1988;27:241–45. doi:https://doi.org/10.1111/j.1365-3083.1988.tb02343.x.
- Coughlin RT, Fattom A, Chu C, White AC, Winston S. Adjuvant activity of QS-21 for experimental E. co/i018 polysaccharide vaccines. Vaccin. 1995;13:17–21. doi:https://doi.org/10.1016/0264-410X(95)80005-X.
- Xie Y, Sun HX, Platycodin LD. D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen. Vaccin. 2009;27(5):757–64. doi:https://doi.org/10.1016/j.vaccine.2008.11.029.
- Xie Y, Sun HX, Platycodin LD. D improves the immunogenicity of Newcastle Disease virus‐based recombinant Avian Influenza vaccine in mice. Chem Biodiv. 2010;7(3):677–89. doi:https://doi.org/10.1002/cbdv.200900183.
- Yendo ACA, de Costa F, Cibulski SP, Teixeira TF, Colling LC, Mastrogiovanni M, Soule S, Roehe PM, Gosmann G, Ferreira FA, et al.. A rabies vaccine adjuvanted with saponins from leaves of the soap tree (Quillaja brasiliensis) induces specific immune responses and protects against lethal challenge. Vaccin. 2016;34(20):2305–11. doi:https://doi.org/10.1016/j.vaccine.2016.03.070.
- Cibulski SP, Silveira F, Mourglia-Ettlin G, Teixeira TF, Dos Santos HF, Yendo AC, de Costa F, Fett-Neto AG, Gosmann G, Roehe PM. Quillaja brasiliensis saponins induce robust humoral and cellular responses in a bovine viral diarrhea virus vaccine in mice. Comp Immun Microbiol. 2016;45:1–8. doi:https://doi.org/10.1016/j.cimid.2016.01.004.
- de Costa F, Yendo ACA, Cibulski SP, Fleck JD, Roehe PM, Spilki FR, Gosmann G, Fett-Neto AG. Alternative inactivated poliovirus vaccines adjuvanted with Quillaja brasiliensis or Quil-A saponins are equally effective in inducing specific immune responses. PLoS One. 2014;9:e105374.
- Silveira F, Cibulski SP, Varela AP, Marques JM, Chabalgoity A, De Costa F, Yendo ACA, Gosmann G, Roehe PM, Fernández C, et al.. Quillaja brasiliensis saponins are less toxic than Quil A and have similar properties when used as an adjuvant for a viral antigen preparation. Vaccin. 2011;29(49):9177–82. doi:https://doi.org/10.1016/j.vaccine.2011.09.137.
- Fleck JD, Kauffmann C, Spilki F, Lencina CL, Roehe PM, Gosmann G. Adjuvant activity of Quillaja brasiliensis saponins on the immune responses to bovine herpesvirus type 1 in mice. Vaccin. 2006;24(49–50):7129–34. doi:https://doi.org/10.1016/j.vaccine.2006.06.09.